Publication: 4435

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
      QxMD      Google Scholar   
Citation:
N Engl J Med vol 392 (1) 45-55
Year:
2025
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
15
Parents:
4200   4371  
Children:
None
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
Merck Sharp & Dohme Corp  
Grants:
U10CA180821, U10CA180882; UG1CA233180, UG1CA233373, UG1CA239767 , UG1CA233290, UG1CA233327, UG1CA233191, UG1CA233160, UG1CA233337, UG1CA233247, UG1CA232760. UG1CA233193, UG1CA233302, UG1CA233196, UG1CA233253, UG1CA233270. U10CA180820 (ECOG-ACRIN); U10CA180888 (SWOG)  
Corr. Author:
 
Authors:
                                                                                 
Networks:
CA043, FL086, IL017, KAISER, KANSAS, LAPS-CT018, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-NC010, LAPS-NY016, LAPS-NY158, LAPS-TN008, LAPS-TX011, MD001   
Study
Alliance-A031501
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: